Business Description
![Aligos Therapeutics Inc Aligos Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000BYXI.png?14)
Aligos Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US01626L1052
Share Class Description:
ALGS: Ordinary SharesDescription
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.61 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.11 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -7.39 | |||||
Beneish M-Score | -3.42 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 48.1 | |||||
3-Year EPS without NRI Growth Rate | 50 | |||||
3-Year FCF Growth Rate | 45.6 | |||||
3-Year Book Growth Rate | -41.1 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.43 | |||||
9-Day RSI | 52.25 | |||||
14-Day RSI | 52.65 | |||||
6-1 Month Momentum % | -40.67 | |||||
12-1 Month Momentum % | -37.22 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.23 | |||||
Quick Ratio | 4.23 | |||||
Cash Ratio | 4.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.1 | |||||
Shareholder Yield % | 3.82 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1173.94 | |||||
Net Margin % | -950.61 | |||||
FCF Margin % | -1070.78 | |||||
ROE % | -110.22 | |||||
ROA % | -65.26 | |||||
ROIC % | -451.71 | |||||
ROC (Joel Greenblatt) % | -944.92 | |||||
ROCE % | -100.75 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.34 | |||||
PB Ratio | 0.63 | |||||
Price-to-Tangible-Book | 0.64 | |||||
EV-to-EBIT | 0.43 | |||||
EV-to-EBITDA | 0.45 | |||||
EV-to-Revenue | -5.08 | |||||
EV-to-FCF | 0.47 | |||||
Price-to-Net-Current-Asset-Value | 0.75 | |||||
Price-to-Net-Cash | 0.82 | |||||
Earnings Yield (Greenblatt) % | 232.56 | |||||
FCF Yield % | -199.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALGS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aligos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 7.967 | ||
EPS (TTM) ($) | -24.285 | ||
Beta | 2.02 | ||
Volatility % | 92.15 | ||
14-Day RSI | 52.65 | ||
14-Day ATR ($) | 1.311995 | ||
20-Day SMA ($) | 13.16129 | ||
12-1 Month Momentum % | -37.22 | ||
52-Week Range ($) | 8.705 - 30 | ||
Shares Outstanding (Mil) | 3.2 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aligos Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aligos Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Aligos Therapeutics Inc Frequently Asked Questions
What is Aligos Therapeutics Inc(ALGS)'s stock price today?
The current price of ALGS is $13.55. The 52 week high of ALGS is $30.00 and 52 week low is $8.71.
When is next earnings date of Aligos Therapeutics Inc(ALGS)?
The next earnings date of Aligos Therapeutics Inc(ALGS) is 2024-11-01 Est..
Does Aligos Therapeutics Inc(ALGS) pay dividends? If so, how much?
Aligos Therapeutics Inc(ALGS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |